Characteristics | All Patients n = 98 | Central Tumors n = 57 | Ultracentral tumors n = 41 | p-value |
---|---|---|---|---|
Age at SBRT completion (years) | 0.242 | |||
Median | 74.0 | 75.2 | 71.7 | |
Range | 43.6–89.6 | 55.4–89.6 | 43.6–85.3 | |
Gender | 0.701 | |||
Male | 42 (42.9%) | 23 (40.4%) | 19 (46.3%) | |
Female | 56 (57.1%) | 34 (59.6%) | 22 (53.7%) | |
ECOG performance status | 0.282 | |||
0 | 16 (16.3%) | 11 (19.3%) | 5 (12.2%) | |
1 | 55 (56.1%) | 34 (59.6%) | 21 (51.2%) | |
2 | 24 (24.5%) | 10 (17.5%) | 14 (34.1%) | |
3 | 3 (3.1%) | 2 (3.5%) | 1 (2.4%) | |
Smoking status | 0.336 | |||
Active smoker | 27 (27.6%) | 18 (31.6%) | 9 (22.0) | |
Past smoker | 56 (57.1%) | 29 (50.9%) | 27 (65.9%) | |
Never smoker | 15 (15.3%) | 10 (17.5%) | 5 (12.2%) | |
COPD | 0.249 | |||
GOLD stage 1 | 15 (15.3%) | 12 (21.1%) | 3 (7.3) | |
GOLD stage 2 | 29 (29.6%) | 13 (22.8%) | 16 (39.0%) | |
GOLD stage 3 | 13 (13.3%) | 8 (14.0%) | 5 (12.2%) | |
GOLD stage 4 | 2 (2.0%) | 1 (1.8%) | 1 (2.4%) | |
GOLD stage unknown | 2 (2.0%) | 2 (3.5%) | 0 (0%) | |
No COPD | 37 (37.8%) | 21 (36.8%) | 16 (39.0%) | |
Age-adjusted Charlson comorbidity index | 0.942 | |||
Median | 7 | 7 | 7 | |
Range | 4–11 | 4–11 | 4–11 | |
Histology | 0.378 | |||
Primary lung tumors | 76 (77.6%) | 46 (80.7%) | 30 (73.2%) | |
Metastases | 22 (22.4%) | 11 (19.7%) | 11 (26.8%) | |
T stage for primary lung tumors | 0.304 | |||
T1a | 2 (2.0%) | 2 (3.5%) | 0 (0%) | |
T1b | 25 (25.5%) | 16 (28.1%) | 9 (22.0%) | |
T1c | 25 (25.5%) | 17 (29.8%) | 8 (19.5%) | |
T2a | 17 (17.3%) | 7 (12.3%) | 10 (24.4%) | |
T2b | 4 (4.1%) | 2 (3.5%) | 2 (4.9%) | |
T3 | 2 (2.0%) | 2 (3.5%) | 0 (0%) | |
T4 | 1 (1.0%) | 0 (0%) | 1 (2.4%) | |
Criteria to define central lung tumors | n/a | n/a | ||
1 – GTV within 2 cm of proximal bronchial tree | 24 (24.5%) | 24 (42.1%) | ||
2 – PTV overlaps mediastinal / pericardial pleura | 31 (31.6%) | 31 (54.4%) | ||
1 and 2 | 2 (2.0%) | 2 (3.5%) | ||
Criteria to define ultracentral lung tumors | n/a | n/a | ||
1 – PTV overlaps proximal bronchial tree | 26 (26.5%) | 26 (63.4%) | ||
2 – PTV overlaps esophagus | 1 (1.0%) | 1 (2.4%) | ||
3 – PTV overlaps pulmonary artery | 2 (2.0%) | 2 (4.9%) | ||
4 – PTV overlaps pulmonary vein | 2 (2.0%) | 2 (4.9%) | ||
1 and 3 | 8 (8.2%) | 8 (19.5%) | ||
1 and 4 | 1 (1.0%) | 1 (2.4%) | ||
2 and 4 | 1 (1.0%) | 1 (2.4%) |